ACADIA Pharmaceuticals Inc.
ACAD
Peringkat dalam Saham
#4507
ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily... ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
Harga Saham
$19.76
Terakhir disinkronkan: 2026-10-19
Kapitalisasi Pasar
$3.40B
Perubahan (1 hari)
3.32%
Perubahan (1 tahun)
-5.66%
Negara
US
Perdagangan ACADIA Pharmaceuticals Inc. (ACAD)
Kategori
Healthcare
Laba untuk ACADIA Pharmaceuticals Inc. (ACAD)
Laba pada Jun 2026 TTM: $121.37M
Menurut laporan keuangan terbaru dari ACADIA Pharmaceuticals Inc., laba saat ini perusahaan adalah $121.37M. Pada tahun 2023, perusahaan memperoleh laba sebesar $-51.04M, peningkatan dibandingkan laba tahun 2022 sebesar $-213.44M. Laba yang ditampilkan di halaman ini adalah laba sebelum bunga dan pajak, atau disebut juga EBIT.
Riwayat laba untuk ACADIA Pharmaceuticals Inc. dari 2000 hingga 2026
Laba pada akhir setiap tahun
| Tahun | Laba | Mengubah |
|---|---|---|
| 2026 (TTM) | $121.37M | -52.97% |
| 2024 | $258.08M | -605.67% |
| 2023 | $-51.04M | -76.09% |
| 2022 | $-213.44M | 27.41% |
| 2021 | $-167.52M | -40.38% |
| 2020 | $-280.97M | 19.88% |
| 2019 | $-234.38M | -3.92% |
| 2018 | $-243.94M | -15.38% |
| 2017 | $-288.28M | 6.75% |
| 2016 | $-270.05M | 64.55% |
| 2015 | $-164.11M | 77.47% |
| 2014 | $-92.48M | 143.69% |
| 2013 | $-37.95M | 82.01% |
| 2012 | $-20.85M | -8.42% |
| 2011 | $-22.77M | -250.37% |
| 2010 | $15.14M | -133.53% |
| 2009 | $-45.15M | -29.73% |
| 2008 | $-64.24M | 13.93% |
| 2007 | $-56.39M | 25.18% |
| 2006 | $-45.05M | 31.97% |
| 2005 | $-34.14M | 31.71% |
| 2004 | $-25.92M | 0.00% |
| 2003 | 0.00 | 0.00% |
| 2002 | 0.00 | 0.00% |
| 2001 | 0.00 | 0.00% |
| 2000 | 0.00 | 0.00% |
Laba untuk perusahaan serupa atau pesaing
| Perusahaan | Laba | Perbedaan Laba | Negara |
|---|---|---|---|
| $5.27B | 4,246.20% |
US
|
|
| $-3.09B | -2,643.50% |
US
|
|
| $-4.02B | -3,409.11% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 1,507.22% |
NL
|
